News & Events

Clinical Program BL8040

BioLineRx Announces Clinical Research Collaboration to Investigate Combination of BL-8040 with Atezolizumab in Multiple Oncology Indications

BioLineRx Ltd. (NASDAQ/TASE: BLRX) today […]

BioLineRx Reports Successful Top-Line Results in Phase 2 Trial for AML

BioLineRx (NASDAQ/TASE: BLRX) announced today […]

BioLineRx Announces Initiation of Phase 2 Trial for BL-8040 as Novel Stem Cell Mobilization Treatment

BioLineRx Ltd. (NASDAQ/TASE:BLRX) announced today […]

BioLineRx Announces Collaboration with MSD to investigate the combination of KEYTRUDA® (pembrolizumab) and BL-8040 in Pancreatic Cancer

BioLineRx Ltd. (NASDAQ/TASE: BLRX) today […]

Pre-Clinical Program

Biokine Announces Issuance of European Patent

Biokine Therapeutics Announces Issuance of […]

Biokine Announces Issuance of Mexican Patent

Biokine Therapeutics Announces Issuance of […]

Biokine Therapeutics Announces Issuance of United States Patent covering the composition and use of peptides for inhibiting chemokine binding to chemokine receptors

Biokine Therapeutics Announces Issuance of […]

Biokine Therapeutics Announces Issuance of Japanese Patent covering the composition and use of polypeptides

Biokine Therapeutics Announces Issuance of […]